AstraZeneca PLC (AZN.L)
| Previous close | 8,863.00 |
| Open | 8,892.00 |
| Bid | 9,006.00 x 0 |
| Ask | 9,009.00 x 0 |
| Day's range | 8,873.00 - 9,029.00 |
| 52-week range | 6,499.80 - 9,081.00 |
| Volume | 1,220,638 |
| Avg. volume | 2,281,705 |
| Market cap | 118.097B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 41.40 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.02 (2.37%) |
| Ex-dividend date | 12 Aug 2021 |
| 1y target est | N/A |
- Business Wire
AstraZeneca Announces Winners and Recognizes Oncology Change Makers in Third Annual Cancer Community Awards
WILMINGTON, Del., October 20, 2021--AstraZeneca, in partnership with Scientific American Custom Media, today announced the winners of the third annual Cancer Community Awards (or C2 Awards). A part of the AstraZeneca YOUR Cancer program, the C2 Awards celebrate diverse individuals and organizations creating meaningful change in the lives of people with cancer and their loved ones across five unique categories.
- Business Wire
IMFINZI Plus Tremelimumab Significantly Improved Overall Survival in HIMALAYA Phase III Trial in 1st-Line Unresectable Liver Cancer
WILMINGTON, Del., October 15, 2021--Positive high-level results from the HIMALAYA Phase III trial showed a single, high priming dose of tremelimumab added to IMFINZI® (durvalumab) demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit versus sorafenib as a 1st-line treatment for patients with unresectable hepatocellular carcinoma (HCC) who had not received prior systemic therapy and were not eligible for localized treatment. This novel dose and schedule
- Business Wire
Tezepelumab granted Orphan Drug Designation in the US for eosinophilic esophagitis
WILMINGTON, Del., October 08, 2021--Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE).
